176 related articles for article (PubMed ID: 20198372)
1. Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Cancer Chemother Pharmacol; 2011 Jan; 67(1):75-82. PubMed ID: 20198372
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
[TBL] [Abstract][Full Text] [Related]
3. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
Lee MS; Mamon HJ; Hong TS; Choi NC; Fidias PM; Kwak EL; Meyerhardt JA; Ryan DP; Bueno R; Donahue DM; Jaklitsch MT; Lanuti M; Rattner DW; Fuchs CS; Enzinger PC
Oncologist; 2013; 18(3):281-7. PubMed ID: 23429739
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F; Masi G; Fornaro L; Vasile E; Allegrini G; Fontana E; Granetto C; Salvatore L; Mentuccia L; Andreuccetti M; Cortesi E; Merlano M; Cascinu S; Falcone A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):559-66. PubMed ID: 20237927
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
8. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.
Watkins JM; Zauls AJ; Kearney PL; Shirai K; Ruppert BN; Harper JL; Sherman CA; Aguero EG; Reed CE; Sharma AK
Jpn J Clin Oncol; 2011 Mar; 41(3):334-42. PubMed ID: 21084436
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Ajani JA; Fairweather J; Pisters PW; Charnsangavej C
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):19-21. PubMed ID: 11200143
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Dank M; Zaluski J; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Cisar L; Wang K; Bugat R
Ann Oncol; 2008 Aug; 19(8):1450-1457. PubMed ID: 18558665
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan, cisplatin, and radiation in esophageal cancer.
Ilson DH; Minsky B; Kelsen D
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
[TBL] [Abstract][Full Text] [Related]
13. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
Ilson DH; Bains M; Kelsen DP; O'Reilly E; Karpeh M; Coit D; Rusch V; Gonen M; Wilson K; Minsky BD
J Clin Oncol; 2003 Aug; 21(15):2926-32. PubMed ID: 12885811
[TBL] [Abstract][Full Text] [Related]
15. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Mason DP; Rodriguez CP; Ives DI
J Thorac Oncol; 2009 Oct; 4(10):1264-9. PubMed ID: 19668013
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
Ilson DH; Minsky BD; Ku GY; Rusch V; Rizk N; Shah M; Kelsen DP; Capanu M; Tang L; Campbell J; Bains M
Cancer; 2012 Jun; 118(11):2820-7. PubMed ID: 21990000
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
